Tanezumab - Eli Lilly and Company/Pfizer
Alternative Names: PF-04383119; PF-4383119; Raylumis; RI-624; RN-624Latest Information Update: 11 Jun 2024
At a glance
- Originator Eli Lilly and Company; Rinat Neuroscience
- Developer Eli Lilly and Company; Pfizer
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Back pain; Cancer pain; Diabetic neuropathies; Musculoskeletal pain; Postherpetic neuralgia
Most Recent Events
- 13 Apr 2024 Efficacy data from a phase II trial in Cancer pain presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 05 Jan 2022 Adverse events data of a phase III OA SAFETY STUDY in patients with Osteoarthritis (OA) presented at ACR Convergence 2021 (ACR/ARP-2021)
- 05 Jan 2022 Pooled adverse events data from phase III trials in Osteoarthritis presented at ACR Convergence 2021 (ACR/ARP-2021)